Eri Toda Kato
Eri Toda Kato
Kyoto University Graduate School of Medicine
Verified email at
Cited by
Cited by
Dapagliflozin and cardiovascular outcomes in type 2 diabetes
SD Wiviott, I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, ...
New England Journal of Medicine 380 (4), 347-357, 2019
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome …
TA Zelniker, SD Wiviott, I Raz, K Im, EL Goodrich, MP Bonaca, ...
The Lancet 393 (10166), 31-39, 2019
Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal …
TA Zelniker, SD Wiviott, I Raz, KA Im, EL Goodrich, RHM Furtado, ...
Circulation 139 (17), 2022-2031, 2019
Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus
ET Kato, MG Silverman, O Mosenzon, TA Zelniker, A Cahn, RHM Furtado, ...
Circulation 139 (22), 2528-2536, 2019
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
O Mosenzon, SD Wiviott, A Cahn, A Rozenberg, I Yanuv, EL Goodrich, ...
The lancet Diabetes & endocrinology 7 (8), 606-617, 2019
Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF–TIMI 48 trial
ET Kato, RP Giugliano, CT Ruff, Y Koretsune, T Yamashita, RG Kiss, ...
Journal of the American Heart Association 5 (5), e003432, 2016
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial
SD Wiviott, I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, ...
American Heart Journal 200, 83-89, 2018
DECLARE‐TIMI 58: participants’ baseline characteristics
I Raz, O Mosenzon, MP Bonaca, A Cahn, ET Kato, MG Silverman, ...
Diabetes, Obesity and Metabolism 20 (5), 1102-1110, 2018
Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
ET Kato, CP Cannon, MA Blazing, E Bohula, S Guneri, JA White, ...
Journal of the American Heart Association 6 (11), e006901, 2017
The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2-TIMI 51 trial
MA Cavender, CM Gibson, E Braunwald, SD Wiviott, SA Murphy, ...
European Heart Journal: Acute Cardiovascular Care 4 (5), 468-474, 2015
Nutrition in transition from Homo sapiens to Homo economicus
RB Singh, T Takahashi, T Nakaoka, K Otsuka, E Toda, HH Shin, MK Lee, ...
The Open Nutraceuticals Journal 6 (1), 2013
Essential and non-essential amino acids in relation to glutamate
T Takahashi, E Toda, R B Singh, F De Meester, A Wilczynska, D Wilson, ...
The Open Nutraceuticals Journal 4 (1), 2011
Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation
ET Kato, S Goto, RP Giugliano
Ageing Research Reviews 49, 115-124, 2019
Infl ammatory mediators in chronic heart failure in North India
J Fedacko, RB Singh, A Gupta, K Hristova, E Toda, A Kumar, M Saxena, ...
Acta Cardiologica 69 (4), 391-398, 2014
Important regulatory role of activated platelet-derived procoagulant activity in the propagation of thrombi formed under arterial blood flow conditions
N Tamura, I Kitajima, Y Kawamura, E Toda, Y Eguchi, H Ishida, S Goto
Circulation Journal 73 (3), 540-548, 2009
Efficacy and safety of edoxaban for the management of elderly patients with atrial fibrillation: ENGAGE AF-TIMI 48
E Toda Kato, RP Giugliano, CT Ruff, SA Murphy, F Nordio, T Kimura, J Jin, ...
Circulation 130 (suppl_2), A16612-A16612, 2014
Intravascular ultrasound-guided percutaneous coronary interventions with minimum contrast volume for prevention of the radiocontrast-induced nephropathy: report of two cases
N Ogata, T Matsukage, E Toda, S Tamiya, T Fujii, G Nakazawa, N Masuda, ...
Cardiovascular intervention and therapeutics 26 (1), 83-88, 2011
Angiographic evaluation of right upper-limb arterial anomalies: implications for transradial coronary interventions.
T Fujii, N Masuda, S Tamiya, M Shima, E Toda, D Ito, G Nakazawa, ...
The Journal of invasive cardiology 22 (11), 536-540, 2010
DECLARE-TIMI 58: design and baseline characteristics
I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, MG Silverman, ...
Diabetes 66, A333-A333, 2017
The system can't perform the operation now. Try again later.
Articles 1–19